(Q38182087)

English

Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials

scientific article published on 21 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

0 references

Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

30 August 2017

Helicobacter pylori

0 references

Helicobacter pylori infectious disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Musthafa Chalikandy Peedikayil

1

1 reference

Europe PubMed Central

30 August 2017

Fahad Ibrahim Alsohaibani

2

1 reference

Europe PubMed Central

30 August 2017

Abdullah Hamad Alkhenizan

3

1 reference

Europe PubMed Central

30 August 2017

language of work or name

0 references

publication date

21 January 2014

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

9

1 reference

Europe PubMed Central

30 August 2017

1

1 reference

Europe PubMed Central

30 August 2017

e85620

1 reference

Europe PubMed Central

30 August 2017

copyright license

Creative Commons Attribution 4.0 International

21 January 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Effectiveness and safety of proton pump inhibitor and levofloxacin based first-line triple therapy in the eradication of Helicobacter pylori: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Evolution of Helicobacter pylori therapy from a meta-analytical perspective.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

6 September 2017

Helicobacter pylori as a pathogen and carcinogen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

23 June 2018

High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multi-central, randomized, controlled clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Levofloxacin based regimens for the eradication of Helicobacter pylori

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

31 August 2018

Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3897467

1 October 2018

Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: A multicentre study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0085620

21 January 2018

Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/24465624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report

1 reference

https://pubmed.ncbi.nlm.nih.gov/24465624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levofloxacin in first-line treatment of Helicobacter pylori infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/24465624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland

1 reference

https://pubmed.ncbi.nlm.nih.gov/24465624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levofloxacin in first-line eradication regimens for Helicobacter pylori: better test antibiotic susceptibility before treating

1 reference

https://pubmed.ncbi.nlm.nih.gov/24465624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24465624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran

1 reference

https://pubmed.ncbi.nlm.nih.gov/24465624

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0085620

1 reference

Europe PubMed Central

30 August 2017

2014PLoSO...985620P

0 references

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38182087&oldid=1862990920"